BIO Wants 14 Years Of Data Exclusivity For Biosimilars; Will Waxman Buy It?
Executive Summary
Biotechnology Industry Organization CEO Jim Greenwood has drawn a line in the sand over follow-on biologics: he will not accept less than 14 years of data exclusivity for innovator products. And he says he has the data to back it up
You may also be interested in...
Follow-On Biologics Under Eshoo’s Bill Not A “Viable Business,” Sandoz Says
No pharmaceutical company will develop follow-on biologics if anything close to the brand-friendly legislation introduced by Rep. Anna Eshoo, D-Calif., to create a regulatory pathway is passed by Congress, Sandoz Biopharmaceuticals head Hannes Teissl said
Follow-On Biologics Under Eshoo’s Bill Not A “Viable Business,” Sandoz Says
No pharmaceutical company will develop follow-on biologics if anything close to the brand-friendly legislation introduced by Rep. Anna Eshoo, D-Calif., to create a regulatory pathway is passed by Congress, Sandoz Biopharmaceuticals head Hannes Teissl said
War Of The White Papers: Grabowski Returns FOB Fire In Debate On Exclusivity
Duke University Economics Professor Henry Grabowski has returned fire in the academic debate over the amount of time brand companies need to recoup their investment in new biologic products